ArticleJHEP reports : innovation in hepatology2025
Intratumoral microbial heterogeneity in HCC reveals a potential therapeutic target.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global research on the crosstalk between microbiota - intratumoral microorganisms and liver cancer: a visualization analysis.Infectious agents and cancer · 2026Article
- Gut microbiota-metabolism axis in digestive tumors: Emerging targets for novel therapies (Review).Experimental and therapeutic medicine · 2026Review
- Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.Journal of gastroenterology and hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its therapeutic challenges are largely influenced by the complexity of the tumor microenvironment (TME). This study aimed to characterize intratumoral microbial heterogeneity, explore its role within the TME, and identify potential antitumor mechanisms and novel microbial targets. Methods: A total of 113 tissue samples, including HCC tumor tissues (n = 48), matched adjacent normal tissues (n = 48), and normal liver tissues from patients with hepatic hemangioma (n = 17), were collected from patients at the Second Hospital of Nanjing, Nanjing Hospital affiliated to Nanjing University of Chinese Medicine. Microbial profiling was performed using 2bRAD-M sequencing, followed by microbial subtyping based on TME features. Metabolomic characterization of microbial subtypes was conducted via ultra-performance liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry. Functional validation was performed Results: Indicator species analysis, differential abundance analysis, and correlation with clinicopathological features identified Conclusions: This study characterized intratumoral microbial communities and their metabolic heterogeneity in HCC, demonstrating that Impact and implications: This study provides scientific evidence supporting the existence and biological relevance of intratumoral microbiota in hepatocellular carcinoma (HCC), identifying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.